Dr. Gregory S. Willis

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies. Dr. Gaillard is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy.

Dr. Armstrong works primarily in the area of women's malignancies, with a particular emphasis on breast cancer, ovarian cancer and other gynecologic malignancies, and the genetics of breast and ovarian cancer. She directs the medical gynecologic oncology clinical service and oversees therapeutic clinical trials in gynecologic cancers. Dr. Armstrong's clinical focus is on the development of new therapeutic approaches to the treatment of breast cancer and gynecologic malignancies. Particular areas of interest are intraperitoneal therapy in ovarian cancer and targeted biologic therapies. Dr. Armstrong also directs the Kimmel Cancer Center's Breast and Ovarian Cancer Screening Service, a genetic counseling service that focuses on identifying patients at risk for cancer and examination of new strategies for cancer screening and prevention. Dr. Armstrong has lectured locally, nationally and internationally. She is active in the Gynecologic Oncology Group, serving on the Medical Oncology, Developmental Therapeutics and Phase I GOG committees and as chair of several clinical trials through this group. She is a representative of the Southwest Oncology Group to the Gynecologic Cancer Steering Committee of the National Cancer Institute. Dr. Armstrong also serves as a representative of Johns Hopkins to the National Cooperative Cancer Network serving on the ovarian cancer and breast cancer risk reduction panels. She has participated as a member of the Cancer Working Group for the Office of Research on Women's Health for the National Institutes of Health, as a scientific reviewer for the breast and ovarian cancer research programs of the Department of Defense and the National Cancer Institute, as a reviewer for the NCI Special Emphasis Panel for Insight Awards to Stamp Out Breast Cancer and as a member of the NCI SPORE Program parent committee. Dr. Armstrong also is co-principal investigator for the NCI National Clinical Trials Network (NCTN) Lead Academic Participating Site (LAPS) at Johns Hopkins, now the major avenue for adult oncology clinical trials in the country. Recent work includes immune checkpoint inhibitor therapy in endometrial cancers with microsatellite instability and PARP inhibition in ovarian cancer. Dr. Armstrong is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Testicular Yolk Sac Tumor, and Ovarian Cancer.

Dr. Rebecca Stone is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. Dr. Stone is a highly skilled surgeon with expertise in laparoscopic and robotic surgery for gynecologic tumors. She also serves as director of the Gynecology Enhanced Recovery after Surgery initiative, an innovative, multidisciplinary program that improves recovery and healing time after major abdominal surgery, as well as minimizes health care costs for patients. Dr. Stone received her undergraduate degree in biology from the University of Virginia. She earned her medical degree from the University of Virginia School of Medicine, where she subsequently completed her residency in obstetrics and gynecology. Dr. Stone performed a four-year gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. She also earned a master’s degree in cancer biology from the University of Texas in 2010. Prior to joining Johns Hopkins, Dr. Stone was an assistant professor at the University of Arkansas for Medical Sciences, where she was one of five gynecologic oncologists serving the entire state. Dr. Stone is internationally recognized for her research pertaining to early diagnosis and treatment of ovarian cancer. She is widely published in the field of gynecologic oncology, with first-author papers in the New England Journal of Medicine and Lancet Oncology, as well as over 40 co-authored manuscripts in peer-reviewed medical journals. She was honored with an award for one of the most influential papers published in the field of obstetrics and gynecology in 2012 and with an Ovarian Cancer Research Fund Grant for “Unplugging Ovarian Cancer from the Power of Platelets.” Dr. Stone strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life. She enjoys working with community providers so that patients are comforted by receiving care close to home. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Ovarian Carcinosarcoma. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.